Proove looks forward to playing an important role in the Precision Medicine Initiative - Brian Meshkin, Founder and CEO
Irvine, CA (PRWEB) January 29, 2015
In the State of the Union address last week, President Obama announced the launch of a new Precision Medicine Initiative - a measure proposed to give the American public wider access to each individual’s personal genetic information.
“21st century businesses will rely on American science, technology, research and development,” President Obama said. “I want the country that eliminated polio and mapped the human genome to lead a new era of medicine -- one that delivers the right treatment at the right time.[...]Tonight, I'm launching a new Precision Medicine Initiative to bring us closer to curing diseases like cancer and diabetes -- and to give all of us access to the personalized information we need to keep ourselves and our families healthier.”
“As a leader in the personalized medicine industry, Proove is hopeful about the upcoming Precision Medicine Initiative,” stated Brian Meshkin, founder and CEO of Proove Biosciences. “Personalized medicine is the future of healthcare and our greatest wish is for everyone to have access to such informative and powerful information. With the impact we are already having with our award-winning research and clinical adoption of our tests, Proove looks forward to playing an important role in this effort.”
About Proove Biosciences
Our Mission is to Change the Future of Medicine. Proove is the proof to improve healthcare decisions. We seek to realize a future when clinicians look back and wonder how they could’ve ever prescribed medications without knowing how a patient would respond. With offices in Southern California and the Baltimore-Washington metropolitan area, the Company is the research leader investigating and publishing data on the genetics of personalized pain medicine with clinical research sites across the United States. Physicians use Proove Biosciences testing to improve outcomes – both safety and efficacy of medical treatment. From a simple cheek swab collected in the office, Proove performs proprietary genetic tests in its CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications. For more information, please visit http://www.proove.com or call toll free 855-PROOVE-BIO (855-776-6832).